Focused Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Focused Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,000	Closed	-$1.57M	–	233
2024 Q1	$1.57M	Buy	+18,000	New	+$1.61M	0.24%	47
2022 Q4	–	Sell	-3,000	Closed	-$3K	–	1100
2022 Q3	$3K	Buy	+3,000	New	+$267K	﹤0.01%	687
2019 Q1	–	Sell	-5,500	Closed	-$4K	–	700
2018 Q4	$4K	Buy	+5,500	New	+$523K	﹤0.01%	556

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Focused Wealth Management's BMRN Position: Q2 2024 in Review

Focused Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 600 shares — an estimated $52.4K sold.

Focused Wealth Management first reported a position in BMRN in Q4 2021 and held it in 2 quarters. The position peaked at $52.4K in Q1 2024. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Focused Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Focused Wealth Management sold 600 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $52.4K.
Focused Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Focused Wealth Management's BioMarin Pharmaceuticals position peaked at $52.4K in Q1 2024.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Focused Wealth Management's 13F filing for Q2 2024, filed 30 Jul 2024.